Tacrolimus vs Neoral in renal and renal/pancreas transplantation

In a retrospective analysis we compared the outcome of a group of 63 kidney or kidney/pancreas transplant recipients who were transplanted between June 1994 and February 1997 and received either tacrolimus (FK, n=22) or Neoral (NEO, n=41) as part of a triple immunosuppressive protocol. Ten patients in the NEO group had recurrent rejection episodes between 1 and 8 months post‐transplant and were converted to FK. CellCept was the secondary immunosuppressive agent in about half the FK, three‐quarters of the NEO, and in all but one in the conversion (CON) groups. Patients in all groups were on prednisone in equal amounts. Mean duration of follow‐up for FK, NEO and CON groups was 32, 19 and 13 months, respectively. One‐yr patient and graft survival was 100% in all groups. At 2 yr, graft survival was 95, 96 and 100% in FK, NEO and CON groups, respectively. Acute rejection at 1 yr was twice as high in the NEO group as the FK group. There were no rejection episodes among the FK patients who also received CellCept. The mean current serum creatinines (mg%) were: FK=1.6, NEO=1.8, CON=1.9. Recurrent infection was more common with FK (8/22) than NEO (1/31) (p=0.023). Our experience suggests there is less rejection but more infection in recipients treated with FK compared to NEO. In patients with recurrent rejection, conversion from NEO to FK stabilizes renal function and minimizes subsequent rejection episodes.